Page last updated: 2024-09-21

3,5-dibromotyrosine

Description

3,5-dibromotyrosine: used to synthesize various secondary metabolites from marine sponges [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10833
CHEMBL ID1253341
CHEBI ID80912
SCHEMBL ID145218
MeSH IDM0220064

Synonyms (42)

Synonym
unii-1996zxq53j
einecs 208-661-9
nsc 39452
1996zxq53j ,
nsc-39452
537-24-6
nsc39452
tyrosine,5-dibromo-
NCI60_001771
NSC210786 ,
biotiren
3,5-dibromotyrosine
nsc97935
dibromotirina
nsc-97935
bromotiren
.beta.-(3,5-dibromo-4-hydroxyphenyl)alanine
l-tyrosine,5-dibromo-
tyrosine,5-dibromo-, l-
2-amino-3-(3,5-dibromo-4-hydroxyphenyl)propanoic acid
3,5-dibromo-tyrosine
C17080
AKOS005109959
chebi:80912 ,
CHEMBL1253341 ,
bdbm50326563
3,5-dibromo-dl-tyrosine
FT-0614516
SCHEMBL145218
MS-3024
dibromotyrosine, dl-
tyrosine, 3,5-dibromo-
dl-3,5-dibromotyrosine
sr-01000310096
SR-01000310096-1
h-3,5-dibromo-tyr-oh
h-3,5-dibromo-d-tyr-oh
Q27151412
dl-dibromotyrosine
FT-0715640
2-amino-3-(3,5-dibromo-4-hydroxyphenyl)propanoicacid
DTXSID50870497

Drug Classes (1)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Receptor-type tyrosine-protein phosphatase alphaHomo sapiens (human)IC50 (µMol)4.60004.60004.60004.6000AID513952
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
integrin-mediated signaling pathwayReceptor-type tyrosine-protein phosphatase alphaHomo sapiens (human)
insulin receptor signaling pathwayReceptor-type tyrosine-protein phosphatase alphaHomo sapiens (human)
modulation of chemical synaptic transmissionReceptor-type tyrosine-protein phosphatase alphaHomo sapiens (human)
regulation of focal adhesion assemblyReceptor-type tyrosine-protein phosphatase alphaHomo sapiens (human)
protein dephosphorylationReceptor-type tyrosine-protein phosphatase alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
protein tyrosine phosphatase activityReceptor-type tyrosine-protein phosphatase alphaHomo sapiens (human)
transmembrane receptor protein tyrosine phosphatase activityReceptor-type tyrosine-protein phosphatase alphaHomo sapiens (human)
protein bindingReceptor-type tyrosine-protein phosphatase alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
plasma membraneReceptor-type tyrosine-protein phosphatase alphaHomo sapiens (human)
focal adhesionReceptor-type tyrosine-protein phosphatase alphaHomo sapiens (human)
membraneReceptor-type tyrosine-protein phosphatase alphaHomo sapiens (human)
extracellular exosomeReceptor-type tyrosine-protein phosphatase alphaHomo sapiens (human)
synaptic membraneReceptor-type tyrosine-protein phosphatase alphaHomo sapiens (human)
Schaffer collateral - CA1 synapseReceptor-type tyrosine-protein phosphatase alphaHomo sapiens (human)
receptor complexReceptor-type tyrosine-protein phosphatase alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID513952Inhibition of human cytoplasmic protein tyrosine phosphatase A assessed as change in enzyme activity at pH 72010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Identification of novel inhibitors for a low molecular weight protein tyrosine phosphatase via virtual screening.
AID513949Effect on human cytoplasmic protein tyrosine phosphatase B assessed as change in enzyme activity at 100 uM at pH 52010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Identification of novel inhibitors for a low molecular weight protein tyrosine phosphatase via virtual screening.
AID513947Effect on human cytoplasmic protein tyrosine phosphatase A assessed as change in enzyme activity at 100 uM at pH 52010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Identification of novel inhibitors for a low molecular weight protein tyrosine phosphatase via virtual screening.
AID1751483Antibiofilm activity against Staphylococcus aureus assessed as biofilm formation at 100 uM measured by crystal violet staining based microplate reader assay2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Discovery of non-proteinogenic amino acids inhibiting biofilm formation by S. aureus and methicillin-resistant S. aureus.
AID1751482Antibacterial activity in Staphylococcus aureus assessed as bacterial growth rate at 100 uM measured by UV absorbance based analysis2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Discovery of non-proteinogenic amino acids inhibiting biofilm formation by S. aureus and methicillin-resistant S. aureus.
AID513948Effect on human cytoplasmic protein tyrosine phosphatase A assessed as change in enzyme activity at 100 uM at pH 72010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Identification of novel inhibitors for a low molecular weight protein tyrosine phosphatase via virtual screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (13.33)18.7374
1990's2 (13.33)18.2507
2000's5 (33.33)29.6817
2010's5 (33.33)24.3611
2020's1 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (6.67%)5.53%
Reviews1 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (86.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]